Literature DB >> 24266529

Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.

Marie Stentebjerg-Olesen1, Pia Jeppesen, Anne K Pagsberg, Anders Fink-Jensen, Sandeep Kapoor, Raja Chekuri, Maren Carbon, Aseel Al-Jadiri, Taishiro Kishimoto, John M Kane, Christoph U Correll.   

Abstract

OBJECTIVE: The use of early response/nonresponse (ER/ENR) to antipsychotics as a predictor for ultimate response/nonresponse (UR/UNR) may help decrease inefficacious treatment continuation. However, data have been limited to adults, and ER/ENR has only been determined using time-consuming psychopathology rating scales. In the current study, we assessed if early improvement on the Clinical Global Impressions-Improvement (CGI-I) scale predicted UR/UNR in psychiatrically ill youth started on antipsychotic treatment.
METHODS: Seventy-nine youth aged 6-19 years, with schizophrenia spectrum disorders, treated naturalistically with aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone and evaluated monthly, were divided into ER/ENR groups at week 4, using at least "minimally improved" on the CGI-I scale. Prediction using week 4 ER/ENR status for UR (CGI-I=at least "much improved"), effectiveness and adverse effect outcomes at 8-12 weeks were assessed.
RESULTS: At 4 weeks, 45.6% of subjects were ER and 54.4% were ENR without differences regarding baseline demographic, illness, and treatment variables, except for higher age (p=0.034) and maximum risperidone dose (p=0.0043) in ENR. ER/ENR status at 4 weeks predicted UR/UNR at week 12 significantly (p<0.0001): Sensitivity=68.9%, specificity=85.3%, positive predictive value=86.1%, negative predictive value=67.4%. At weeks 4, 8, and 12, ER patients improved significantly more on the CGI-I, CGI-Severity, and Children's Global Assessment of Functioning scales, and more ER patients reached UR compared with ENR patients (83.3% vs. 34.9%, all p<0.0001). ENR patients had more extrapyramidal side effects (EPS) at weeks 4, 8, and 12 (p=0.0019-0.0079). UR was independently associated with ER (odds ratio [OR]=18.09; 95% confidence interval [CI]=4.71-91.68, p<0.0001) and psychosis not otherwise specified (NOS) (OR=4.82 [CI: 1.31-21.41], p=0.017) (r(2)=0.273, p<0.0001).
CONCLUSIONS: Older age and EPS were associated with ENR; ENR and schizophrenia were associated with UNR in naturalistically treated youth with schizophrenia spectrum disorders. Early CGI-I-based treatment decisions require further consideration and study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24266529      PMCID: PMC3870605          DOI: 10.1089/cap.2013.0007

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  39 in total

1.  Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.

Authors:  Ofer Agid; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Journal:  Arch Gen Psychiatry       Date:  2003-12

2.  Early prediction of antipsychotic response in schizophrenia.

Authors:  Christoph U Correll; Anil K Malhotra; Saurabh Kaushik; Marjorie McMeniman; John M Kane
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

Review 3.  Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia.

Authors:  R Wilbur; F A Kulik; A V Kulik
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1988       Impact factor: 5.067

4.  A rating scale for drug-induced akathisia.

Authors:  T R Barnes
Journal:  Br J Psychiatry       Date:  1989-05       Impact factor: 9.319

5.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

6.  A rating scale for extrapyramidal side effects.

Authors:  G M Simpson; J W Angus
Journal:  Acta Psychiatr Scand Suppl       Date:  1970

7.  Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.

Authors:  A Chatterjee; M Chakos; A Koreen; S Geisler; B Sheitman; M Woerner; J M Kane; J Alvir; J A Lieberman
Journal:  Am J Psychiatry       Date:  1995-12       Impact factor: 18.112

8.  A children's global assessment scale (CGAS).

Authors:  D Shaffer; M S Gould; J Brasic; P Ambrosini; P Fisher; H Bird; S Aluwahlia
Journal:  Arch Gen Psychiatry       Date:  1983-11

9.  Treatment of neuroleptic-resistant schizophrenic relapse.

Authors:  B J Kinon; J M Kane; C Johns; R Perovich; M Ismi; A Koreen; P Weiden
Journal:  Psychopharmacol Bull       Date:  1993

10.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Authors:  John M Kane; Stefan Leucht; Daniel Carpenter; John P Docherty
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

View more
  8 in total

1.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

2.  Therapeutic abstention in the treatment of depression in first-episode psychosis.

Authors:  Priyadharshini Sabesan; Lena Palaniyappan
Journal:  J Psychiatry Neurosci       Date:  2020-11       Impact factor: 6.186

3.  Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.

Authors:  Ditte L Vernal; Sandeep Kapoor; Aseel Al-Jadiri; Eva M Sheridan; Yehonathan Borenstein; Charles Mormando; Lisa David; Sukhbir Singh; Andrew J Seidman; Maren Carbon; Miriam Gerstenberg; Ema Saito; John M Kane; Hans-Christoph Steinhausen; Christoph U Correll
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-09       Impact factor: 2.576

Review 4.  The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.

Authors:  Peter M Haddad; Christoph U Correll
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-08

Review 5.  Clinical predictors of therapeutic response to antipsychotics in schizophrenia.

Authors:  Maren Carbon; Christoph U Correll
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

Review 6.  Prediction of treatment outcomes in psychiatry--where do we stand ?

Authors:  Francis J McMahon
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

7.  Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.

Authors:  Anne Katrine Pagsberg; Pia Jeppesen; Dea Gowers Klauber; Karsten Gjessing Jensen; Ditte Rudå; Marie Stentebjerg-Olesen; Peter Jantzen; Simone Rasmussen; Eva Ann-Sofie Saldeen; Maj-Britt Glenn Lauritsen; Niels Bilenberg; Anne Dorte Stenstrøm; Jesper Pedersen; Louise Nyvang; Sarah Madsen; Marlene B Lauritsen; Ditte Lammers Vernal; Per Hove Thomsen; Jakob Paludan; Thomas M Werge; Kristian Winge; Klaus Juul; Christian Gluud; Maria Skoog; Jørn Wetterslev; Jens Richardt M Jepsen; Christoph U Correll; Anders Fink-Jensen; Birgitte Fagerlund
Journal:  BMC Psychiatry       Date:  2014-07-11       Impact factor: 3.630

8.  Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial.

Authors:  Minhan Dai; Yulu Wu; Yiguo Tang; Weihua Yue; Hao Yan; Yamin Zhang; Liwen Tan; Wei Deng; Qi Chen; Guigang Yang; Tianlan Lu; Lifang Wang; Fude Yang; Fuquan Zhang; Jianli Yang; Keqing Li; Luxian Lv; Qingrong Tan; Hongyan Zhang; Xin Ma; Lingjiang Li; Chuanyue Wang; Xiaohong Ma; Dai Zhang; Hao Yu; Liansheng Zhao; Hongyan Ren; Yingcheng Wang; Xun Hu; Guangya Zhang; Xiaodong Du; Qiang Wang; Tao Li
Journal:  BJPsych Open       Date:  2020-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.